Showing 2 posts of 2 posts found.
Takeda is to scrap an advanced trial of an investigational drug after it failed to show any benefit in survival …
Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation